CHAPTER 1. Infections in Patients with Cancer: Overview by Amar Safdar, Gerald Bodey, Donald Armstrong

ABSTRACT

Patients with neoplastic disease are often highly susceptible to severe infections. The following factors influence the types, severity and response to therapy of these infections. 1) Changing epidemiology of infections; 2) Cancer- and/or treatment-associated neutropenia; 3) Acquired immune deficiency states such as cellular immune defect; 4) Recent development of new generation diagnostic tools including widely available DNA amplification tests; 5) Effective intervention for infection prevention; 6) Empiric or presumptive therapy during high-risk risk periods; 7) Availability of new classes of highly active antimicrobial drugs; 8) Strategies to promote hosts’ immune response, and 9) Future measures. This introductory chapter intended for the reader to become familiar with the important historical milestones in the understanding and development in the field of infectious diseases in immunosuppressed patients with an underlying neoplasms and patients undergoing hematopoietic stem cell transplantation.

Rague J, Huang J, Khan S, Dubrovskaya Y, Press R & Safdar A. Initial High Serum (1, 3) β-D-Glucan (BDG) in Hospitalized Adult Patients: Impact on Treatment Outcomes and Hospital Mortality. (Abstract 51976). IDSA and SHEA Annual Meeting; IDWeek. October 7-11, 2015 San Diego, CA

Taff J, Tang K, Dubrovskaya Y, Press R & Safdar A. Evaluation of Human Coronavirus HKU1, NL63, OC43 and C229E Infections in 176 Patients at a Tertiary Care Medical Center in New York. (Poster # V-1382) ASM’s Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) & International Society of Chemotherapy (ISC)’s International Congress of Chemotherapy and Infection (ICC). September 17–21, 2015 | San Diego, CA

Khan S, Huang J, Rauge J, Dubrovskaya Y, Press R & Safdar A. Serum (1,3) β-D-Glucan (BDG) to Assess Response to Antifungal Therapy and Predict Short-term Mortality in 275 Patients at a Major University Medical Center in New York. (Poster # D-726) ASM’s Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) & International Society of Chemotherapy (ISC)’s International Congress of Chemotherapy and Infection (ICC). September 17–21, 2015 | San Diego, CA

Taff J, Dubrovskaya Y, Kudlowitz D, Sartori D, Mulliken J & Safdar A. Risk Factors and Predictors for Lung Disease in Patients with Human Metapneumovius Infection at a Major University Hospital in New York. The 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Copenhagen, Denmark. April 25-28th, 2015.

Safdar A. Successful Therapy with Aerosolized 7% Hypertonic Saline in Patients with Severe Refractory Pulmonary Nontuberculous Mycobacteriosis (pNTM). The 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Copenhagen, Denmark. April 25-28th, 2015.

Safdar A. Challenges in effective treatment for patients with nontuberculous mycobacterial lung disease. The 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Copenhagen, Denmark. April 25-28th, 2015.

Torres JA, Dubrovskaya Y, Teperman J, Press R & Safdar A. Serial Procalcitonin in Critically Ill Patients including Solid-Organ Transplantation (SOT) Recipients with Infection or Infection-Like Syndrome may Predict Outcomes. IDWeek 2014TM, Philadelphia, PA. October 8-12, 2014

Dubrovskaya Y, Siegfried J, Flagiello T, Scipione MR, Chen D, Phillips M, Papadopoulos J, & Safdar A. Role of Metronidazole vs. Vancomycin as Initial Therapy in Hospitalized Patients with Mild to Moderate Clostridium difficile Infection (CDI) with NAP1 vs. non-NAP1 Disease. (45539). IDWeek 2014TM, Philadelphia, PA. October 8-12, 2014

Safdar A, Goff D, Gallagher J, Hsu D, Eiland E, Hanrahan J, Smith P, Azie N. Antifungal Stewardship: The Clinician’s Perspective on Barriers to Implementation. IDWeek 2014TM, Philadelphia, PA. October 8-12, 2014